The US Food and Drug Administration Commissioner Stephen Hahn defended the agency’s decision making during the COVID-19 pandemic as being rooted in “good data and sound science,” while acknowledging that it has made risk-benefit decisions on medical products using “data sets that might not be as robust as they would under normal circumstances.”
In a speech given over teleconference to the Alliance For A Stronger FDA on Monday, Hahn also said that FDA...






